Signant adds DSG’s solution suite to its own capabilities to grow CRO and sponsor services.
Signant Health has acquired DSG – a 20-year-old provider of electronic data capture (EDC) and direct data capture (DDC) technology for site-based and decentralized clinical trials. DSG will become a Signant company, and Signant will add the DSG capabilities to its digital solutions for clinical trials, including eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics.
The DSG solution suite was chosen based on the following criteria: (1) ease of use – where sites in particular provided positive feedback; (2) operational efficiency – combines rapid study start up times with workflow tools and remote SDV capabilities; (3) flexibility –accommodates the requirements of both simple and complex study designs; and (4) customer support.
“We believe DSG is the industry’s best kept secret. We are excited to welcome the DSG team to Signant, enabling us to extend our product suite to include comprehensive EDC/DDC capabilities,” said Roger Smith, Signant’s chief executive officer.
Reference: Signant Acquires DSG to Enhance Its eClinical Solution Suite for Traditional and Decentralized Clinical Trials. PHILADELPHIA, PA – July 17, 2023. https://www.signanthealth.com/company/newsroom/item/signant-acquires-dsg-to-enhance-its-eclinical-solution-suite-for-traditional-and-decentralized-clinical-trials/
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.